JP2008508298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508298A5 JP2008508298A5 JP2007523776A JP2007523776A JP2008508298A5 JP 2008508298 A5 JP2008508298 A5 JP 2008508298A5 JP 2007523776 A JP2007523776 A JP 2007523776A JP 2007523776 A JP2007523776 A JP 2007523776A JP 2008508298 A5 JP2008508298 A5 JP 2008508298A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- disease
- pharmaceutical composition
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 12
- 206010039491 Sarcoma Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 9
- 230000001684 chronic effect Effects 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 208000025865 Ulcer Diseases 0.000 claims 6
- 108091008605 VEGF receptors Proteins 0.000 claims 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 6
- 229940111134 coxibs Drugs 0.000 claims 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 206010023332 keratitis Diseases 0.000 claims 6
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- 231100000397 ulcer Toxicity 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 239000003098 androgen Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 3
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical group C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
- 108010036949 Cyclosporine Proteins 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108010008165 Etanercept Proteins 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 3
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 229940119534 Lysophosphatidic acid acyltransferase inhibitor Drugs 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 108091033399 Telomestatin Proteins 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 229960001265 ciclosporin Drugs 0.000 claims 3
- 229960003405 ciprofloxacin Drugs 0.000 claims 3
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 229930182912 cyclosporin Natural products 0.000 claims 3
- 229960003901 dacarbazine Drugs 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960001776 edrecolomab Drugs 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 3
- 229960005073 erlotinib hydrochloride Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 230000003394 haemopoietic effect Effects 0.000 claims 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229960005280 isotretinoin Drugs 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 229960001476 pentoxifylline Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 229950003647 semaxanib Drugs 0.000 claims 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- -1 statin Substances 0.000 claims 3
- 229940063683 taxotere Drugs 0.000 claims 3
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- 229960005267 tositumomab Drugs 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 3
- 229960004528 vincristine Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 3
- 229960002066 vinorelbine Drugs 0.000 claims 3
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 3
- 206010068532 5q minus syndrome Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 2
- 206010002064 Anaemia macrocytic Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 208000019878 Eales disease Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 2
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 2
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000028606 Optic disc pit Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000019269 advanced heart failure Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000021328 arterial occlusion Diseases 0.000 claims 2
- 239000010425 asbestos Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 230000005796 circulatory shock Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 210000004177 elastic tissue Anatomy 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 208000007565 gingivitis Diseases 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000029824 high grade glioma Diseases 0.000 claims 2
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000035984 keratolysis Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 230000004130 lipolysis Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 201000006437 macrocytic anemia Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 210000004412 neuroendocrine cell Anatomy 0.000 claims 2
- 230000000683 nonmetastatic effect Effects 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 210000004786 perivascular cell Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 238000010837 poor prognosis Methods 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000028172 protozoa infectious disease Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 229910052895 riebeckite Inorganic materials 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000006476 shipyard eye Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 201000009295 smoldering myeloma Diseases 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 206010044325 trachoma Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/900,332 US7405237B2 (en) | 2004-07-28 | 2004-07-28 | Isoindoline compounds and methods of their use |
| PCT/US2005/026679 WO2006015060A2 (en) | 2004-07-28 | 2005-07-27 | Isoindoline compounds and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508298A JP2008508298A (ja) | 2008-03-21 |
| JP2008508298A5 true JP2008508298A5 (enExample) | 2009-02-12 |
Family
ID=35733185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523776A Pending JP2008508298A (ja) | 2004-07-28 | 2005-07-27 | イソインドリン化合物及びそれらの使用法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7405237B2 (enExample) |
| EP (1) | EP1781610A2 (enExample) |
| JP (1) | JP2008508298A (enExample) |
| KR (1) | KR20070047807A (enExample) |
| CN (1) | CN101031545A (enExample) |
| AU (1) | AU2005269367B2 (enExample) |
| BR (1) | BRPI0513836A (enExample) |
| CA (1) | CA2574966A1 (enExample) |
| IL (1) | IL180978A0 (enExample) |
| MX (1) | MX2007000842A (enExample) |
| NZ (1) | NZ553029A (enExample) |
| WO (1) | WO2006015060A2 (enExample) |
| ZA (1) | ZA200701660B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0315316A (pt) * | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
| JP2006507324A (ja) * | 2002-11-06 | 2006-03-02 | セルジーン・コーポレーション | 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法 |
| WO2005110085A2 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| EP1896007B1 (en) * | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| DK1907373T3 (da) * | 2005-06-30 | 2013-02-04 | Celgene Corp | Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser |
| WO2007107305A2 (en) | 2006-03-22 | 2007-09-27 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| TW200806625A (en) * | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| US20120149716A1 (en) | 2009-02-10 | 2012-06-14 | Zeldis Jerome B | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| JP5918694B2 (ja) * | 2009-05-12 | 2016-05-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ |
| CN101580501B (zh) * | 2009-06-01 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体 |
| AU2010290822A1 (en) * | 2009-09-03 | 2012-03-29 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CN101747255B (zh) * | 2009-12-22 | 2011-11-23 | 上海大学 | 含烯炔结构的异吲哚酮类化合物及其合成方法 |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN103026229B (zh) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | 用于治疗银屑病的生物标志物 |
| CN104045594B (zh) * | 2012-02-21 | 2016-08-17 | 四川大学 | 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途 |
| CN102603610B (zh) * | 2012-02-21 | 2014-07-09 | 四川大学 | 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途 |
| KR101441096B1 (ko) * | 2012-11-27 | 2014-09-25 | 가톨릭대학교 산학협력단 | 제피티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
| KR102223060B1 (ko) | 2013-04-17 | 2021-03-05 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법 |
| CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
| EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| TW201617331A (zh) * | 2014-07-08 | 2016-05-16 | Ｖｉｉｖ醫療保健英國有限公司 | 異吲哚啉衍生物 |
| WO2017015484A1 (en) | 2015-07-23 | 2017-01-26 | Temple University-Of The Commonwealth System Of Higher Education | Novel aminothiazole compounds and methods using same |
| US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
| US10941126B2 (en) | 2017-01-19 | 2021-03-09 | Temple University-Of The Commonwealth System Of Higher Education | Bridged bicycloalkyl-substituted aminothiazoles and their methods of use |
| AU2018321548B2 (en) | 2017-08-21 | 2023-03-09 | Celgene Corporation | Processes for preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate |
| US11976059B2 (en) | 2018-08-16 | 2024-05-07 | Korea Research Institute Of Chemical Technology | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer |
| JP7736275B2 (ja) * | 2019-12-26 | 2025-09-09 | オハイオ ステート イノベーション ファウンデーション | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
| CN114644586A (zh) * | 2022-04-12 | 2022-06-21 | 江苏豪森药业集团有限公司 | 一种来那度胺有关物质的制备方法 |
| WO2025118133A1 (zh) * | 2023-12-05 | 2025-06-12 | 浙江普洛家园药业有限公司 | 一种(s)-来那度胺-5-位衍生物及其合成方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1035848E (pt) | 1997-07-31 | 2003-09-30 | Celgene Corp | Acidos alcano-hidroxamicos substituidos e metodo de reducao dos niveis de tnf alfa |
| CA2361806C (en) * | 1999-03-18 | 2012-03-13 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| CA2457319C (en) | 2001-08-06 | 2011-07-05 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
-
2004
- 2004-07-28 US US10/900,332 patent/US7405237B2/en active Active
-
2005
- 2005-07-27 JP JP2007523776A patent/JP2008508298A/ja active Pending
- 2005-07-27 EP EP05775526A patent/EP1781610A2/en not_active Withdrawn
- 2005-07-27 MX MX2007000842A patent/MX2007000842A/es active IP Right Grant
- 2005-07-27 AU AU2005269367A patent/AU2005269367B2/en not_active Expired
- 2005-07-27 ZA ZA200701660A patent/ZA200701660B/xx unknown
- 2005-07-27 WO PCT/US2005/026679 patent/WO2006015060A2/en not_active Ceased
- 2005-07-27 BR BRPI0513836-1A patent/BRPI0513836A/pt not_active IP Right Cessation
- 2005-07-27 CA CA002574966A patent/CA2574966A1/en not_active Abandoned
- 2005-07-27 NZ NZ553029A patent/NZ553029A/en not_active IP Right Cessation
- 2005-07-27 CN CNA2005800327224A patent/CN101031545A/zh active Pending
- 2005-07-27 KR KR1020077004729A patent/KR20070047807A/ko not_active Ceased
-
2007
- 2007-01-25 IL IL180978A patent/IL180978A0/en unknown
-
2008
- 2008-02-15 US US12/070,322 patent/US7569597B2/en not_active Expired - Lifetime
-
2009
- 2009-08-04 US US12/535,642 patent/US7816393B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508298A5 (enExample) | ||
| JP6026441B2 (ja) | キナーゼ阻害剤としてのアミノキノリン | |
| US6608053B2 (en) | Fused heteroaryl derivatives | |
| US6642228B1 (en) | α1b-adrenergic receptor antagonists | |
| WO2002094809A1 (fr) | Derives de 3-quinoleine-2-(1h)-ylideneindoline-2-one | |
| JP5585892B2 (ja) | キナーゼ阻害剤としての化合物 | |
| CN105764905B (zh) | 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基 | |
| CA2486141A1 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| JPWO2019212990A5 (enExample) | ||
| JP2007510670A5 (enExample) | ||
| WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
| BR112021005091A2 (pt) | heterociclos funcionalizados como agentes antivirais | |
| JP2006508131A5 (enExample) | ||
| CN110770234A (zh) | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 | |
| US9012659B2 (en) | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
| US20040116497A1 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents | |
| RU2165420C2 (ru) | 1,2,5-тиадиазольные производные индолилалкил-пиримидинил-пиперазинов и фармацевтическая композиция на их основе | |
| TWI753229B (zh) | 用於治療癌症之組合療法 | |
| WO2006077851A1 (ja) | キノロン誘導体又はその塩 | |
| US20040097539A1 (en) | Hsp inductor | |
| JP3810017B2 (ja) | 縮合ヘテロアリール誘導体 | |
| JP2024534044A (ja) | Ｄｄｒ１の阻害剤としてのフェニルおよびピリドピラゾール誘導体 | |
| JPWO2022066734A5 (enExample) | ||
| US20240190827A1 (en) | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | |
| JP4351444B2 (ja) | ファルネシルトランスフェラーゼを阻害する４−ヘテロシクリル−キノリンおよびキナゾリン誘導体 |